Literature DB >> 27249217

Correction: High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity.

.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0151508.].

Year:  2016        PMID: 27249217      PMCID: PMC4889103          DOI: 10.1371/journal.pone.0156923

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


The following information is missing from the Competing Interests statement: Calciscon AG holds a patent for the T50-Test and markets the T50-Test. The publisher apologizes for this error. The complete, correct Competing Interests statement is: The authors have the following interests. This study was supported by an unrestricted grant from Fresenius MC, Bad Homburg, Germany. Bernard Canaud is employed by Fresenius MC and holds shares in this company. Andreas Pasch is a part-time employee of Calciscon and holds shares in this company. Mauro Dionisi and Matthias Meier are both employed by Calciscon. Calciscon AG holds a patent for the T50-Test and markets the T50-Test. There are no other patents, products in development or marketed products to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
  1 in total

1.  High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity.

Authors:  Marijke Dekker; Andreas Pasch; Frank van der Sande; Constantijn Konings; Matthias Bachtler; Mauro Dionisi; Matthias Meier; Jeroen Kooman; Bernard Canaud
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.